Guangzhou Innogen Pharmaceutical Group Co., Ltd - Laporan Laba Rugi (TTM)

Guangzhou Innogen Pharmaceutical Group Co., Ltd
HK ˙ SEHK
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Guangzhou Innogen Pharmaceutical Group Co., Ltd menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2025
03-31
2025
06-30
Revenue 28 56
Change (%) 100.00
% of Revenue 100.00 100.00
Cost Of Sales 3 6
Change (%) 100.00
% of Revenue 10.55 10.55
Gross Operating Profit 25 50
Change (%) 100.00
% of Revenue 89.45 89.45
SG&A 110 132
Change (%) 20.76
% of Revenue 388.31 234.46
R&D 126 150
Change (%) 18.71
% of Revenue 446.80 265.19
OpEx 240 291
Change (%) 21.16
% of Revenue 851.29 515.71
Operating Income -212 -235
Change (%) 10.67
% of Revenue -751.29 -415.71
Interest Expense -1 -0
Change (%) -34.51
% of Revenue -2.30 -0.75
Net Income -198 -222
Change (%) 11.90
% of Revenue -702.57 -393.09

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista